PC-029 · GLP-1 · retatrutide
Retatrutide
LY3437943
Also: Triple G
§ Overview
A triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — the first 'triple G' therapy. In Phase 2 trials, Retatrutide produced up to 24% body weight loss at 48 weeks, the highest ever recorded for an anti-obesity drug. Currently in Phase 3 trials by Eli Lilly.
§ Mechanism
Simultaneously activates three receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (potentiates GLP-1 effects, energy expenditure), and GCGR (glucagon receptor — increases energy expenditure, promotes fat oxidation, reduces hepatic steatosis). The triple mechanism explains superior efficacy.
§ Common Uses
- → Obesity/weight loss
- → Type 2 diabetes
- → NASH/fatty liver
- → Metabolic syndrome
§ Reported Side Effects
- · Nausea
- · Diarrhea
- · Vomiting
- · Constipation
- · Decreased appetite
§ Research, Experiences & Trends
Mechanism of Action
Simultaneously activates three receptors: GLP-1R (appetite suppression, insulin secretion), GIPR (potentiates GLP-1 effects, energy expenditure), and GCGR (glucagon receptor — increases energy expenditure, promotes fat oxidation, reduces hepatic steatosis). The triple mechanism explains superior efficacy.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite